Last reviewed · How we verify
Intensive antiplatelet
Intensive antiplatelet is a Antiplatelet agent combination Small molecule drug developed by Beijing Tiantan Hospital. It is currently in Phase 3 development for Acute coronary syndrome, Secondary prevention of thrombotic events in high-risk patients. Also known as: Dual antiplatelet.
Intensive antiplatelet therapy inhibits platelet aggregation through multiple pathways to reduce thrombotic events.
There is no verified information about intensive antiplatelet therapy in the provided facts. However, based on the information, Aspirin is a small molecule (ChEMBL) and has been studied as an intervention for various conditions, including Cardiovascular Diseases and Stroke, on ClinicalTrials.gov.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Intensive antiplatelet |
|---|---|
| Also known as | Dual antiplatelet |
| Sponsor | Beijing Tiantan Hospital |
| Drug class | Antiplatelet agent combination |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This approach typically combines two or more antiplatelet agents (such as aspirin and P2Y12 inhibitors) to provide enhanced inhibition of platelet function through different mechanisms. By blocking multiple pathways of platelet activation and aggregation, intensive antiplatelet regimens aim to reduce the risk of thrombotic complications in high-risk cardiovascular patients.
Approved indications
- Acute coronary syndrome
- Secondary prevention of thrombotic events in high-risk patients
Common side effects
- Bleeding
- Gastrointestinal hemorrhage
- Intracranial hemorrhage
Key clinical trials
- Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion (PHASE3)
- Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period (PHASE4)
- Symptomatic Carotid Outcomes Registry
- Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Comparative Study (PHASE4)
- Traditional Chinese Medicine Intervention for Ischemic Cardiovascular Disease Comorbid With Diabetes Mellitus: An Efficacy Comparative Study (PHASE4)
- Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community (NA)
- Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction (PHASE4)
- Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intensive antiplatelet CI brief — competitive landscape report
- Intensive antiplatelet updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI
Frequently asked questions about Intensive antiplatelet
What is Intensive antiplatelet?
How does Intensive antiplatelet work?
What is Intensive antiplatelet used for?
Who makes Intensive antiplatelet?
Is Intensive antiplatelet also known as anything else?
What drug class is Intensive antiplatelet in?
What development phase is Intensive antiplatelet in?
What are the side effects of Intensive antiplatelet?
Related
- Drug class: All Antiplatelet agent combination drugs
- Manufacturer: Beijing Tiantan Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Secondary prevention of thrombotic events in high-risk patients
- Also known as: Dual antiplatelet
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing